Alcresta Investment Reflects Omega Market Growth

Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.

Venture capital firms collectively invested $10 million in nutritionals start-up Alcresta, in a vote of confidence for the expanding omega oil market.

More from Clinical Trials

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By 

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By 

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

Political Influence And The US FDA: A New Era?

 

FDA Commissioner Martin Makary declared during an interview with former Fox News host Megyn Kelly that there “should be nothing political” about the US FDA, but it feels like politics is infecting the agency in unprecedented ways about three weeks into his tenure.

More from R&D

‘Come Early, Come Often,’ EMA Chief Tells Industry

 

The European Medicines Agency’s chief, Emer Cooke, explained how the agency could help companies with their drug development plans, and said the EU Health Technology Assessment Regulation would help companies design clinical trials that are fit for regulators and HTA bodies.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

Political Influence And The US FDA: A New Era?

 

FDA Commissioner Martin Makary declared during an interview with former Fox News host Megyn Kelly that there “should be nothing political” about the US FDA, but it feels like politics is infecting the agency in unprecedented ways about three weeks into his tenure.